Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Human Papillomavirus 16 Positive Hpv 16 Cancers Epidemiology Forecast

DelveInsight’s ‘Human Papillomavirus 16-positive (HPV16+) Cancers –Epidemiology Forecast—2030’ report delivers an in-depth understanding of Human Papillomavirus 16-positive (HPV16+) Cancers, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5
  • Japan

Study Period: 2018–2030

Human Papillomavirus 16-positive (HPV16+) Cancers Disease Understanding

Human papillomavirus (HPV) is the most common sexually transmitted infection, with a high probability of infection with the virus for both males and females across their lifetime. Although the immune system eliminates most HPV infections without complications, some HPV-induced growths can progress to cancer. HPV 16 is the subtype found in most cancers and accounts for most cases of cervix, penis, vulva, vagina, anus, and oropharynx cancers.


Despite advances in the understanding of the natural history of human papillomavirus infection and its role through persistence as the major risk factor in the development of cervical and other anogenital cancers, primary (vaccination) or secondary prevention programs (cervical screening) can impact decisively in preventing cancer, but both these approaches are not available for many at greatest risk. All those with HPV-driven chronic or neoplastic lesions and cancers potentially require therapy. If surgical removal is not possible or is unsuccessful, then other approaches are necessitated.

Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology

The Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology segmented as the Incident Cases of HPV-induced cancer. The report includes the incident HPV-induced Cancer symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise HPV induced Cancer Epidemiology

The epidemiology segment also provides the HPV-induced Cancer epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


The total incident population of HPV-induced cancer was 99,392 in 2020 and expected to increase for the study period, i.e., 2018–2030.


As per the estimates, amongst the European countries, Germany had the highest incident population of HPV induced Cancer with 12,733 cases, followed by France, which had an incident population of 9,694 in 2020

Scope of the Report

  • Human Papillomavirus 16-positive (HPV16+) Cancers report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology Report and Model provide an overview of the risk factors and global trends of Human Papillomavirus 16-positive (HPV16+) Cancers in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • The report provides insight into the historical and forecasted patient pool of Human Papillomavirus 16-positive (HPV16+) Cancers in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Human Papillomavirus 16-positive (HPV16+) Cancers
  • The report provides the segmentation of the Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology by Incident Cases of HPV induced Cancer in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • The report provides the segmentation of the HPV induced Cancer epidemiology by incident cases in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan

Report Highlights

  • 10-year Forecast of Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology
  • 7MM Countries Coverage
  • Total Incident Cases of Human Papillomavirus 16-positive (HPV16+) Cancers

KOL Views

We interview KOLs, and SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Human Papillomavirus 16-positive (HPV16+) Cancers?
  • What are the key findings of Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, and which type will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of patients with Human Papillomavirus 16-positive (HPV16+) Cancers across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow during the forecast period (2018–2030)?
  • What are the disease risk, burden, and unmet needs of Human Papillomavirus 16-positive (HPV16+) Cancers?
  • What are the currently available treatments for Human Papillomavirus 16-positive (HPV16+) Cancers?

Reasons to buy

The Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Human Papillomavirus 16-positive (HPV16+) Cancers market
  • Quantify patient populations in the global Human Papillomavirus 16-positive (HPV16+) Cancers market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Human Papillomavirus 16-positive (HPV16+) Cancers therapeutics in each of the markets covered
  • Understand the magnitude of Human Papillomavirus 16-positive (HPV16+) Cancers population by its incidence cases
  • The Human Papillomavirus 16-positive (HPV16+) Cancers epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Human Papillomavirus 16-positive (HPV16+) Cancers Epiddemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Human Papillomavirus 16-positive (HPV16+) Cancers in 2018

3.2. Patient Share (%) Distribution of Human Papillomavirus 16-positive (HPV16+) Cancers in 2030

4. Executive Summary of Human Papillomavirus 16-positive (HPV16+) Cancers

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Risk Factors

5.4. Molecular Mechanisms of HPV

5.5. Malignances associated with HPV

5.6. HPV and Cancer Progression

5.7. Diagnosis

5.8. Biomarkers

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Assumption and Rationale

6.3. 7MM Total Incident Patient Population of HPV induced Cancer

6.4. The United States

6.4.1. Incident Cases of HPV induced Cancer in the US

6.5. EU5

6.5.1. Germany

6.5.1.1. Incident Cases of HPV induced Cancer in Germany

6.5.2. France

6.5.2.1. Incident Cases of HPV induced Cancer in France

6.5.3. Italy

6.5.3.1. Incident Cases of HPV induced Cancer in Italy

6.5.4. Spain

6.5.4.1. Incident Cases of Human Papillomavirus 16-positive (HPV16+) Cancers in Spain

6.5.5. United Kingdom

6.5.5.1. Incident Cases of HPV induced Cancer in the UK

6.6. Japan

6.6.1. Incident Cases of HPV induced Cancer in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1: Summary of Human Papillomavirus 16-positive (HPV16+) Cancers, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Incident Cases of Human Papillomavirus 16-positive (HPV16+) Cancers in the 7MM (2018–2030)

Table 3: Incident Cases of HPV induced Cancer in the US (2018–2030)

Table 4: Incident Cases of HPV induced Cancer in Germany (2018–2030)

Table 5: Incident Cases of HPV induced Cancer in France (2018–2030)

Table 6: Incident Cases of HPV induced Cancer in Italy (2018–2030)

Table 7: Incident Cases of Human Papillomavirus 16-positive (HPV16+) Cancers in Spain (2018–2030)

Table 8: Incident Cases of HPV induced Cancer in the UK (2018–2030)

Table 9: Incident Cases of HPV induced Cancer in Japan (2018–2030)

List of Figures

Figure 1: Incident cases of HPV induced Cancer in the 7MM (2018–2030)

Figure 2: Incident Cases of HPV induced Cancer in the US (2018–2030)

Figure 3: Incident Cases of HPV induced Cancer in Germany (2018–2030)

Figure 4: Incident Cases of HPV induced Cancer in France (2018–2030)

Figure 5: Incident Cases of HPV induced Cancer in Italy (2018–2030)

Figure 6: Incident Cases of HPV induced Cancer in Spain (2018–2030)

Figure 7: Incident Cases of HPV induced Cancer in the UK (2018–2030)

Figure 8: Incident Cases of HPV induced Cancer in Japan (2018–2030)

Forward to Friend

Need A Quote